Screener
Tectonic Therapeutics TECX US — Income Tax Reconciliation Tax Credits Research
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tectonic Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationTaxCreditsResearch.
The source filing: Tectonic Therapeutics’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 4:21 PM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-076793
As of December 31, 2025, the Company had $11.9 million of U.S. federal research and development tax credits that begin to expire in 2039. As of December 31, 2025, the Company had $4.9 million of state research and development tax credits that begin to expire at various dates from 2034 through 2040.
Item 16. Form 10-K Summary
FAQ
- What is Tectonic Therapeutics's US — income tax reconciliation tax credits research?
- Tectonic Therapeutics (TECX) reported US — income tax reconciliation tax credits research of $2.98M in Q4 2025.
- What does US — income tax reconciliation tax credits research mean?
- This metric represents the total value of tax credits claimed by the company's US operations specifically related to research and development activities. It serves as a financial indicator of the company's investment in innovation and its ability to utilize government tax incentives to offset operational costs. Tracking this figure helps investors understand the tax-shield benefits derived from the company's ongoing R&D pipeline and scientific discovery efforts.
Ask your AI about Tectonic Therapeutics's us — income tax reconciliation tax credits research.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude